View
[Webinar] One and Not Quite Done: Gene therapy for Hemophilia
Date: Thursday, September 3, 2020 Time: 11am ET / 8am PT Duration: 1 Hour
The original goal of cell and gene therapy was to deliver a single administration that would maintain therapeutic effectiveness over a patient’s lifetime. This ‘one and done’ model appears to have worked for some gene therapies, where promising follow-up data has been observed. In some instances, however, such as in the case of gene therapy for hemophilia, a single dose may not be enough and redosing may be required.
Date: Thursday, September 3, 2020 Time: 11am ET / 8am PT Duration: 1 Hour
The original goal of cell and gene therapy was to deliver a single administration that would maintain therapeutic effectiveness over a patient’s lifetime. This ‘one and done’ model appears to have worked for some gene therapies, where promising follow-up data has been observed. In some instances, however, such as in the case of gene therapy for hemophilia, a single dose may not be enough and redosing may be required.
In this webinar, our speakers will discuss:
Strategies for both one-time and redosing gene therapies
What redosing means for the commercialization strategy
Considerations for manufacturing and market access
Register Now Register Now
Event Information
Event Topic:
One and Not Quite Done: Gene therapy for Hemophilia
Event Description:
Date/Time:
Date(s) - 09/03/20
8:00 am - 9:00 am
Event Location:
Other: Webinar- requires registration
Event Details
Event Type